ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of cancer therapies that address unmet medical needs through synthetic immuno-oncology. The company, through its collaboration agreement with Intrexon Corporation, holds certain rights to Intrexon's synthetic immuno-oncology platform for use in the field of oncology, which includes a clinical stage product candidate, Ad-RTS-IL-12 that is used with the oral activator veledimex and evaluated for the treatment of metastatic melanoma and unresectable recurrent or metastatic breast cancer. The synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer. The company, under its license agreement with The University of Texas MD Anderson Cancer Center, along with Intrexon hold license to certain technologies relating to novel chimeric antigen receptor (CAR) T cell therapies, non-viral gene transfer systems, genetic modification and/or propagation of immune cells and other cellular therapy approaches, Natural Killer cells and T cell receptors. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
ZIOPHARM Oncology Inc. ZIOP shares fell 20.6 percent to $4.50 in the pre-market trading session following a concerning Adam Feuerstein tweet on the company offering. Adam Feuerstein reported a brain tumor patient death following ZIOPHARM’s gene therapy injection.
Its interesting that the technical pattern from yesterday indicated that a break out was coming. This news today sent it spiraling lower!
